60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report sent to investors on Saturday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Tuesday, February 25th.

60 Degrees Pharmaceuticals Trading Down 10.6 %

NASDAQ:SXTP opened at $1.77 on Friday. The firm has a market cap of $2.61 million, a price-to-earnings ratio of -0.18 and a beta of 4.52. The company’s 50-day moving average is $2.86 and its two-hundred day moving average is $4.78. 60 Degrees Pharmaceuticals has a 12-month low of $1.41 and a 12-month high of $35.99.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.